Ozari vs Fifty 410: $133 Tirzepatide That Becomes $183 as Your Dose Climbs

Fifty 410's tirzepatide page publishes three different prices for the same drug: $399, $499, or $549 per three-month program. The difference is milligrams. A starter program costs $133 a month; the 216 mg high-dose program costs $183. Since dose escalation is the normal path in GLP-1 therapy, the tier you start in is rarely the tier you stay in.

What Fifty 410 Publicly Lists

As of August 2026, fifty410.com's pricing pages have listed:

Compounded tirzepatide, 3-month programs (paid once, shipped upfront):

• Starter program: $399 total — $133/month
• Mid-dose program (144 mg total): $499 total — $166/month
• High-dose program (216 mg total): $549 total — $183/month

Compounded semaglutide:

• Monthly option: $199 for a one-month supply

Independent reviewers including Weight Loss Rankings and ClearMetabolic report a semaglutide 3-month bundle working out to roughly $99/month; that tier did not appear in the static pricing page we captured, so verify current bundle pricing directly with Fifty 410.

The purchase structure is genuinely different from most telehealth programs. There is no subscription and no card on file: you complete the intake free, a licensed provider reviews it, and only if approved do you receive a payment link. The entire program's medication then ships at once in refrigerated packaging with free overnight or 2-day shipping. Afterpay, Affirm, and FSA/HSA cards are accepted. Medications come from independent FDA-registered 503A and 503B compounding pharmacies, though the pharmacies are not named on the pricing pages. The site footer displays a LegitScript Approved seal linking to LegitScript's verification tool.

Reputation signals are strong for the category: Trustpilot shows a 4.8 rating across more than 4,100 reviews for fifty410.com as of August 2026. One caution raised by independent reviewers: after the initial approval, Fifty 410 publishes no scheduled check-in cadence, so ongoing dose-adjustment conversations are largely patient-initiated.

How the Models Compare

Fifty 410's model rewards people who dislike subscriptions. Nothing renews, nothing auto-bills, and refill paperwork is a separate, deliberate step. That is a legitimate strength — nobody gets surprise-charged for a program they forgot to cancel.

The trade-offs sit in two places. First, dose-tier pricing: your monthly cost rises as your prescribed dose rises, from $133 toward $183 on tirzepatide. Second, the whole program ships upfront, which means paying for three months of a medication before you know how you tolerate week two.

Ozari runs the opposite structure: flat pricing that does not change with dose. Semaglutide is $86/mo on Ozari One, billed $258 every 3 months, or $145/mo on Ozari Select billed quarterly ($175/mo billed monthly). Tirzepatide is $125/mo on Ozari One, billed $375 every 3 months, or $199/mo on Ozari Select billed quarterly ($235/mo billed monthly). Ozari One ships to every state except California; California patients use Ozari Select, $145/mo billed quarterly for semaglutide or $199/mo for tirzepatide. No membership fee, HSA/FSA accepted, licensed 503A US compounding pharmacies, provider review before any prescription, and intake available across all 50 states.

On semaglutide specifically, the published gap is wide: Fifty 410's listed monthly option is $199; Ozari One is $86/mo billed quarterly and Ozari Select is $145/mo billed quarterly.

The 12-Month Math

Fifty 410, tirzepatide, a realistic escalation year (four 3-month programs):

• Program 1 (starter): $399
• Program 2 (mid-dose): $499
• Programs 3–4 (high-dose): $549 × 2 = $1,098
• Year total: $399 + $499 + $1,098 = $1,996

Staying at the starter dose all year — uncommon, but possible — would run $399 × 4 = $1,596.

Fifty 410, semaglutide, monthly option:

• $199 × 12 = $2,388

Ozari, semaglutide:

• Ozari One semaglutide: $258 every 3 months (about $86/mo)
• Four shipments: $258 × 4 = $1,032
• Year-one total: $1,032

Ozari, tirzepatide:

• Ozari One tirzepatide: $375 every 3 months (about $125/mo)
• Four shipments: $375 × 4 = $1,500
• Year-one total: $1,500

Read the tirzepatide result honestly: Fifty 410's escalation year ($1,996) comes in $496 above Ozari One's $1,500 ($1,996 − $1,500), and even a year spent at Fifty 410's lowest-dose program ($1,596) costs $96 more. Both companies bill in four 3-month blocks. On semaglutide, Ozari One's $1,032 undercuts Fifty 410's monthly-option year by $1,356 ($2,388 − $1,032). Fifty 410's reported $99/month semaglutide bundle would work out to $1,188 a year, still $156 above Ozari One; confirm it exists at checkout before counting on it.

A note from Johanna Galyen, APRN, FNP: Fifty 410 ships your entire three-month program at once, which means the vials for weeks nine through twelve arrive before you know how week two feels. If nausea or fatigue stalls your titration, don't push ahead just because the next dose is already in the fridge — the schedule serves you, not the inventory. And since check-ins after approval are largely patient-initiated here, we suggest a recurring calendar reminder to report how each dose step is actually going.

Key Comparison Table

Before you pay any provider, check it against the eight red flags that rule out a GLP-1 provider.

Neither company here trips these wires. Use the checklist on any GLP-1 seller you evaluate:

• No prescription required. Both Fifty 410 and Ozari route every order through a licensed provider — anyone who doesn't is not a pharmacy, they're a liability.
• "Generic Ozempic" language. No generic semaglutide is FDA-approved in the US.
• Compounded medication described as FDA-approved. Compounded drugs are not FDA-approved, at any provider.
• Unnamed, unverifiable pharmacy. Ask which pharmacy fills the prescription and confirm its state license.
• "Research use only" vials. Not for human use, ever.
• Guaranteed weight-loss numbers. Averages are not promises.

How to Cancel Fifty 410

There is no subscription to cancel. Fifty 410 sells one program at a time: you pay through a secure link only after provider approval, no card stays on file, and refills require submitting new paperwork. To stop treatment, simply don't request the next program. Per Fifty 410's refund policy as of August 2026, you can receive a full refund any time before the pharmacy begins compounding your medication — and a full refund on unshipped medication if you're medically disqualified — but no refund once the order ships. Approved refunds are processed within about five business days, then take another 5–10 to reach your card; Afterpay and Affirm refunds route back through the financing provider. Even without a subscription, keep a paper trail: save the approval email and payment receipt, send any refund request in writing, and screenshot the confirmation. Fifty 410's policy asks you to attempt direct resolution before filing a chargeback, so contact its support first if a charge looks wrong, then your card issuer if it goes unresolved. Ozari publishes its own cancellation and refund terms at https://www.ozarihealth.com/refund-policy

Frequently Asked Questions

Why does Fifty 410's tirzepatide have three prices?

Pricing follows total milligrams per 3-month program: $399 starter, $499 for 144 mg, $549 for 216 mg. As your prescribed dose increases, your program price typically does too.

Is Fifty 410 a subscription?

No. Each program is a one-time purchase, paid only after provider approval. Refills require submitting new paperwork — nothing renews automatically.

How does Ozari handle dose increases?

Ozari's pricing is flat regardless of dose: Ozari One $86/mo billed quarterly or Ozari Select $145/mo quarterly for semaglutide; Ozari One $125/mo billed quarterly or Ozari Select $199/mo quarterly for tirzepatide. A dose change does not change your bill.

Does Fifty 410 have good reviews?

Trustpilot shows a 4.8 rating across more than 4,100 reviews as of August 2026 — among the stronger scores in the compounded GLP-1 category.

Is Fifty 410's medication FDA-approved?

No. Its compounded semaglutide and tirzepatide come from FDA-registered 503A/503B pharmacies but are not FDA-approved products — the same is true of all compounded GLP-1s, including Ozari's.

Do I need to cancel Fifty 410?

No. There is no subscription and no card on file — each program is a one-time purchase, and stopping means not submitting refill paperwork. Refunds are available in full before compounding begins, but not after your medication ships.

Which is cheaper over a year?

On published pricing, Ozari One on both: semaglutide $1,032 vs $2,388 at Fifty 410's monthly option, and tirzepatide $1,500 vs about $1,996 for a Fifty 410 escalation year. Both bill in 3-month blocks. Verify current pricing directly.

Is Fifty 410 legitimate?

Fifty 410 requires licensed provider review and discloses that compounded medications are not FDA-approved, per its published pages. Fifty 410 states it holds LegitScript certification; you can confirm that at legitscript.com and check its pharmacy licensure before ordering.

This article is for informational purposes only and is not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Pricing reflects publicly listed figures as of August 2026 and may change; verify current pricing directly with each provider. Always consult a licensed healthcare provider before starting or changing treatment. Ozari Health connects patients with licensed independent providers who determine whether treatment is appropriate.

Sources

• https://www.fifty410.com/pricing/semaglutide
• https://www.fifty410.com/pricing/tirzepatide
• https://www.fifty410.com/refund-policy (refund eligibility table and no-subscription terms, accessed August 2026)
• https://www.weightlossrankings.org/reviews/fifty-410
• https://clearmetabolic.com/reviews/fifty410-review/
• https://www.trustpilot.com/review/fifty410.com
• https://www.legitscript.com/websites/?checker_keywords=fifty410.com
• https://www.ozarihealth.com/true-cost/fifty-410
• https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss